Niederer Kraft Frey advised Stalicla on its series B financing. Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders has...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised STALICLA SA on the deal. STALICLA SA announced its exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder, neurodevelopmental...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised STALICLA on the deal. STALICLA announced its worldwide in-licensing of SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin, from Evgen Pharma in neurodevelopmental...
You must be a Standard 1 Year member to access this content.
